Free Trial
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Price, News & Analysis

Akari Therapeutics logo
$1.10 +0.01 (+0.45%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$1.10 0.00 (0.00%)
As of 07/25/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Akari Therapeutics Stock (NASDAQ:AKTX)

Key Stats

Today's Range
$1.10
$1.12
50-Day Range
$1.09
$1.42
52-Week Range
$0.85
$4.40
Volume
9,926 shs
Average Volume
20,400 shs
Market Capitalization
$35.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Buy

Company Overview

Akari Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

AKTX MarketRank™: 

Akari Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 515th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Akari Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Akari Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    0.14% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently increased by 24.30%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Akari Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akari Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.14% of the float of Akari Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Akari Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Akari Therapeutics has recently increased by 24.30%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Akari Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Akari Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,120.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 5.06% of the stock of Akari Therapeutics is held by institutions.

  • Read more about Akari Therapeutics' insider trading history.
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Akari Therapeutics (NASDAQ:AKTX) Now Covered by Maxim Group
See More Headlines

AKTX Stock Analysis - Frequently Asked Questions

Akari Therapeutics' stock was trading at $1.22 at the beginning of 2025. Since then, AKTX stock has decreased by 9.4% and is now trading at $1.1050.

Akari Therapeutics PLC (NASDAQ:AKTX) announced its earnings results on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

Akari Therapeutics's stock reverse split on the morning of Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE).

Company Calendar

Last Earnings
3/31/2020
Today
7/25/2025
Next Earnings (Estimated)
8/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKTX
CIK
1541157
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+360.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-213.59%
Return on Assets
-65.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.16
Quick Ratio
0.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.84 per share
Price / Book
1.29

Miscellaneous

Outstanding Shares
32,176,000
Free Float
19,917,000
Market Cap
$34.91 million
Optionable
Not Optionable
Beta
0.21
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AKTX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners